SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing an offer to acquire eBay, fueling investor speculation about a potential strategic pivot into a larger e-commerce marketplace. While the community is debating the feasibility and financing of such a large-scale acquisition, many are focused on the potential for a short squeeze and the stock's significant move on high volume.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense momentum as traders speculate on a potential short squeeze, driven by a high short interest, significant cost-to-borrow fees, and a scarcity of available shares. The community is actively discussing the stock's potential to rally further ahead of upcoming earnings, with many users advocating for a 'diamond hands' strategy to pressure short sellers into covering their positions.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating significant buzz due to its low-float profile and extreme price volatility, which has led to intense speculation about potential short squeezes. Community discussions are heavily focused on the stock's recent performance following a reverse split, with traders debating whether the movement is a genuine breakout or a classic pump-and-dump setup.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio shares are rallying following the company's inclusion in the S&P MidCap 400 index, a move that has sparked renewed momentum among investors. Community sentiment is shifting toward optimism, with many highlighting potential AI-driven voice demand and operational discipline as foundational strengths for the stock's future performance.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as the market reacts to strong box office momentum from the Michael Jackson biopic, fueling investor sentiment around the company's standalone studio potential. Community discussions are heavily focused on the stock's role as a high-conviction buyout candidate, with participants tracking significant institutional accumulation and strategic board moves as potential indicators of an upcoming acquisition.

Dogelon Mars

Dogelon Mars is trending amid persistent community speculation regarding potential token burns and future utility, with holders actively debating whether the project's historical ties to Elon Musk and low market cap offer a contrarian opportunity. While sentiment remains highly polarized between long-term supporters hoping for a resurgence and critics labeling the asset a legacy pump-and-dump, the community continues to mobilize around high-visibility social media activity to drive momentum.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as investors show strong enthusiasm following the "Best New Drug" award for Revuforj and anticipation for key data presentations at the upcoming ASH meeting. The community is actively discussing a potential buyout by Incyte due to strategic synergies, with many highlighting the stock's significant upside potential relative to its current valuation and high short interest.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors weigh strong commercial launch momentum for TONMYA against concerns over proposed corporate governance measures, including authorization for future reverse stock splits. The community is actively debating the company's long-term capital strategy versus the potential for clinical success in the fibromyalgia market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors digest the recent energization of the Sweetwater 1 substation while speculating on future hyperscaler deal flow ahead of upcoming earnings. Community sentiment remains polarized, with many debating the company's execution speed versus the recent decline in share price and ongoing retail frustrations over the timing of corporate communications.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to conservative 2026 financial guidance and the anticipated impact of the TDAPA reimbursement transition, sparking heated community debate over the company's valuation versus its long-term growth potential. While some shareholders are expressing frustration over the recent stock performance and leadership communication, others are actively focused on the upcoming Phase 3 trial results for REZZAYO and ongoing legislative efforts to secure long-term reimbursement for DefenCath.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI

Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...

<ul class="summary-bullets"><li>Underwriters were given a 30-day option to purchase up to 1.74 million additional shares.</li><li>Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary fibrosis.</li><li>The company plans to launch two late-stage clinical trials starting in the second quarter of 2026.</li></ul>Shares of Trevi Therapeutics, Inc. (TRVI) jumped 5% on Friday to an all-time high after the biotech firm priced its $150 million underwritten public offering at $13 per share.<a href="https://stocktwits.com/symbol/TRVI">TRVI shares</a> are heading for a fifth consecutive session of gains, rising nearly 20% over the course of the rally.While Trevi offered 11.6 million shares at $13 per share, it also granted underwriters a 30-day option to purchase up to 1.74 million additional shares that could fetch up to $22.5 million. The offering is expected to close around April 20, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier. Message volumes soared a whopping 600% on the platform over the past 24 hours, according to Stocktwits data.One user called the price action “strange” and questioned if it was driven by a “small squeeze.”<stembedurl>https://stocktwits.com/abcdzepeda/message/650605154</stembedurl>Another user, who commented before the $13 per share offer was disclosed, said the dilution seemed unnecessary.<stembedurl>https://stocktwits.com/socalBB/message/650528771</stembedurl><h2 class="st-heading-2">Trevi Prepares To Launch Late-Stage Trials For Chronic Cough Treatment</h2>Trevi Therapeutics is currently developing Haduvio, its treatment for chronic cough in patients with conditions such as idiopathic pulmonary fibrosis, interstitial lung disease, and refractory chronic cough.Last month, the firm <a href="https://stocktwits.com/news-articles/markets/equity/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE">announced</a> plans to launch two late-stage clinical trials for Haduvio following discussions with the U.S. Food and Drug Administration (FDA). The first trial is expected to begin in the second quarter of 2026, with the second starting later in the year.Both studies will be randomized and placebo-controlled, testing the drug’s safety and effectiveness. One trial will enroll around 300 patients, while the other will include about 130, Trevi added.The stock has seen heavy buying interest over the past year, surging more than 165%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening

The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.

Equity

Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?

Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...

What's Going On With Trevi Therapeutics Stock?

Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.read more...

Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Hastings' departure. Other stocks also dip in pre-market.read more...

Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High - Time to Buy?

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month High - Still a Buy...

Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2% - Here's What Happened

Trevi Therapeutics (NASDAQ:TRVI) Trading 7.2% Higher - Time to Buy...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TRVI News

TRVITrevi Therapeutics Inc